{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:37:15Z","timestamp":1795066635589,"version":"4.10.2"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","award":["No award number"],"award-info":[{"award-number":["No award number"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Long-acting (LA) injectable antiretroviral therapy (ART) has been found non-inferior to daily oral ART in Phase 3 trials. LA ART may address key barriers to oral ART adherence and be preferable to daily pills for some people living with HIV. To date, women have been less represented than men in LA ART research. Using longitudinal data from the Women\u2019s Interagency HIV Study (WIHS) cohort of women living with HIV in the United States, we examined barriers and facilitators of daily oral ART adherence that may be related to or addressed by LA ART.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a secondary analysis of WIHS cohort data from 1998 to 2017 among participants seen for at least 4 visits since 1998 who reported using ART at least once (<jats:italic>n<\/jats:italic>\u2009=\u20092601). Two dichotomous outcomes, patient-reported daily oral ART adherence and viral suppression were fit using generalized linear models, examining the role of socio-demographic and structural factors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At study enrollment, the median age was 40.5\u2009years, 63% of participants were African American and 22% were Latina. The majority (82%) reported taking ART more than 75% of the time and 53% were virally suppressed. In multivariate analysis, several sub-groups of women had lower odds of reported adherence and viral suppression: 1) younger women (adherence aOR: 0.71; viral suppression aOR: 0.63); 2) women who inject drugs (adherence aOR: 0.38; viral suppression aOR: 0.50) and those with moderate (adherence aOR: 0.59; viral suppression aOR: 0.74) and heavy alcohol consumption (adherence aOR: 0.51; viral suppression aOR: 0.69); 3) those with depressive symptoms (adherence aOR: 0.61; viral suppression aOR: 0.76); and 4) those with a history of going on and off ART (adherence aOR: 0.62, viral suppression aOR: 0.38) or changing regimens (adherence aOR: 0.83, viral suppression aOR: 0.56).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Current injectable contraceptive users (vs. non-users) had greater odds of oral ART adherence (aOR: 1.87) and viral suppression (aOR: 1.28). Findings identify profiles of women who may benefit from and be interested in LA ART. Further research is warranted focused on the uptake and utility of LA ART for such key subpopulations of women at high need for innovative approaches to achieve sustained viral suppression.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12905-020-01011-8","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T09:03:42Z","timestamp":1595667822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Lorie","family":"Benning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-9173","authenticated-orcid":false,"given":"Andrea","family":"Mantsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kerrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenell S.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oni","family":"Blackstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Konkle-Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Philbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaora A.","family":"Adimora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardge H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Milam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seble G.","family":"Kassaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"issue":"6","key":"1011_CR1","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2352-3018(17)30029-2","volume":"4","author":"RS Hogg","year":"2017","unstructured":"Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, et al. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. Lancet HIV. 2017;4(6):e270\u2013e6.","journal-title":"Lancet HIV"},{"issue":"9377","key":"1011_CR2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","volume":"362","author":"A Mocroft","year":"2003","unstructured":"Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22\u20139.","journal-title":"Lancet."},{"issue":"13","key":"1011_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853\u201360.","journal-title":"N Engl J Med"},{"issue":"6","key":"1011_CR4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"key":"1011_CR5","volume-title":"Viral suppression for HIV treatment success and prevention of sexual transmission of HIV","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Viral suppression for HIV treatment success and prevention of sexual transmission of HIV 2018 [Available from: https:\/\/www.who.int\/hiv\/mediacentre\/news\/viral-supression-hiv-transmission\/en\/."},{"issue":"Suppl 2","key":"1011_CR6","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1086\/340197","volume":"185","author":"BJ Turner","year":"2002","unstructured":"Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S143\u201351.","journal-title":"J Infect Dis"},{"issue":"3","key":"1011_CR7","first-page":"177","volume":"10","author":"LG Miller","year":"2000","unstructured":"Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Read. 2000;10(3):177\u201385.","journal-title":"AIDS Read"},{"issue":"5","key":"1011_CR8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00126334-200004150-00005","volume":"23","author":"AL Gifford","year":"2000","unstructured":"Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386\u201395.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"1011_CR9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","volume":"15","author":"DR Bangsberg","year":"2001","unstructured":"Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids. 2001;15(9):1181\u20133.","journal-title":"Aids."},{"issue":"5","key":"1011_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QAI.0000000000000082","volume":"65","author":"DB Hanna","year":"2014","unstructured":"Hanna DB, Hessol NA, Golub ET, Cocohoba JM, Cohen MH, Levine AM, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(5):587\u201396.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1011_CR11","doi-asserted-by":"crossref","unstructured":"Blair W, Cox C. Current Landscape of Antiviral Drug Discovery. F1000Res. 2016;5.","DOI":"10.12688\/f1000research.7665.1"},{"issue":"4","key":"1011_CR12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00042560-200004010-00016","volume":"23","author":"S Low-Beer","year":"2000","unstructured":"Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23(4):360\u20131.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1011_CR13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/09540120701244943","volume":"19","author":"AP Hardon","year":"2007","unstructured":"Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658\u201365.","journal-title":"AIDS Care"},{"issue":"2","key":"1011_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/B:AIBE.0000030245.52406.bb","volume":"8","author":"NR Reynolds","year":"2004","unstructured":"Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004;8(2):141\u201350.","journal-title":"AIDS Behav"},{"issue":"11","key":"1011_CR15","doi-asserted-by":"crossref","first-page":"e111421","DOI":"10.1371\/journal.pone.0111421","volume":"9","author":"I Hodgson","year":"2014","unstructured":"Hodgson I, Plummer ML, Konopka SN, Colvin CJ, Jonas E, Albertini J, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One. 2014;9(11):e111421.","journal-title":"PLoS One"},{"issue":"10","key":"1011_CR16","doi-asserted-by":"crossref","first-page":"e108150","DOI":"10.1371\/journal.pone.0108150","volume":"9","author":"CJ Colvin","year":"2014","unstructured":"Colvin CJ, Konopka S, Chalker JC, Jonas E, Albertini J, Amzel A, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PLoS One. 2014;9(10):e108150.","journal-title":"PLoS One"},{"issue":"9","key":"1011_CR17","doi-asserted-by":"crossref","first-page":"e107543","DOI":"10.1371\/journal.pone.0107543","volume":"9","author":"ER Weaver","year":"2014","unstructured":"Weaver ER, Pane M, Wandra T, Windiyaningsih C, Herlina SG. Factors that influence adherence to antiretroviral treatment in an urban population, Jakarta, Indonesia. PLoS One. 2014;9(9):e107543.","journal-title":"PLoS One"},{"issue":"12","key":"1011_CR18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/09540121.2012.672722","volume":"24","author":"C Ortego","year":"2012","unstructured":"Ortego C, Huedo-Medina TB, Santos P, Rodriguez E, Sevilla L, Warren M, et al. Sex differences in adherence to highly active antiretroviral therapy: a meta-analysis. AIDS Care. 2012;24(12):1519\u201334.","journal-title":"AIDS Care"},{"issue":"10","key":"1011_CR19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1086\/522762","volume":"45","author":"M Lazo","year":"2007","unstructured":"Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45(10):1377\u201385.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1011_CR20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11904-011-0098-0","volume":"8","author":"CM Puskas","year":"2011","unstructured":"Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV\/AIDS Rep. 2011;8(4):277\u201387.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"5","key":"1011_CR21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.6061\/clinics\/2013(05)06","volume":"68","author":"BP de Fatima","year":"2013","unstructured":"de Fatima BP, Ceccato M, Rocha GM, de Assis AF, Campos LN, Guimaraes MD. Gender differences in non-adherence among Brazilian patients initiating antiretroviral therapy. Clinics (Sao Paulo). 2013;68(5):612\u201320.","journal-title":"Clinics (Sao Paulo)"},{"key":"1011_CR22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2334-11-86","volume":"11","author":"C Tapp","year":"2011","unstructured":"Tapp C, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1011_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/09540120050123774","volume":"12","author":"KJ Roberts","year":"2000","unstructured":"Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12(4):377\u201386.","journal-title":"AIDS Care"},{"issue":"4","key":"1011_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/apc.2007.0122","volume":"22","author":"P Halkitis","year":"2008","unstructured":"Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDs. 2008;22(4):323\u201335.","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"1011_CR25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00126334-200101010-00012","volume":"26","author":"CA Kleeberger","year":"2001","unstructured":"Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26(1):82\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"1011_CR26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/QAI.0b013e31815ace7e","volume":"47","author":"BW Pence","year":"2008","unstructured":"Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race\/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):194\u2013201.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"1011_CR27","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1371\/journal.pone.0000552","volume":"2","author":"PS Sullivan","year":"2007","unstructured":"Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Nakashima AK. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One. 2007;2(6):e552.","journal-title":"PLoS One"},{"issue":"1","key":"1011_CR28","doi-asserted-by":"crossref","first-page":"e0189973","DOI":"10.1371\/journal.pone.0189973","volume":"13","author":"A Geter","year":"2018","unstructured":"Geter A, Sutton MY, Armon C, Durham MD, Palella FJ Jr, Tedaldi E, et al. Trends of racial and ethnic disparities in virologic suppression among women in the HIV outpatient study, USA, 2010-2015. PLoS One. 2018;13(1):e0189973.","journal-title":"PLoS One"},{"issue":"4","key":"1011_CR29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/09540121.2018.1426827","volume":"30","author":"A Geter","year":"2018","unstructured":"Geter A, Sutton MY, Hubbard MCD. Social and structural determinants of HIV treatment and care among black women living with HIV infection: a systematic review: 2005-2016. AIDS Care. 2018;30(4):409\u201316.","journal-title":"AIDS Care"},{"issue":"8","key":"1011_CR30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/09540121.2019.1612022","volume":"31","author":"ELP Bradley","year":"2019","unstructured":"Bradley ELP, Frazier EL, Carree T, Hubbard McCree D, Sutton MY. Psychological and social determinants of health, antiretroviral therapy (ART) adherence, and viral suppression among HIV-positive black women in care. AIDS Care. 2019;31(8):932\u201341.","journal-title":"AIDS Care"},{"key":"1011_CR31","volume-title":"Long-acting cabotegravir + rilpivirine as maintanence therapy: ATLAS week 48 results","author":"S Swindells","year":"2019","unstructured":"Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Del Mar MM, et al. Long-acting cabotegravir + rilpivirine as maintanence therapy: ATLAS week 48 results. Seattle: Conference on Retroviruses and Opportunistic Infections (CROI); March 4\u20137; 2019."},{"issue":"10101","key":"1011_CR32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499\u2013510.","journal-title":"Lancet."},{"issue":"2","key":"1011_CR33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00001648-199803000-00004","volume":"9","author":"SE Barkan","year":"1998","unstructured":"Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's interagency HIV study. WIHS Collaborative Study Group. Epidemiology. 1998;9(2):117\u201325.","journal-title":"Epidemiology"},{"issue":"9","key":"1011_CR34","first-page":"1013","volume":"12","author":"MC Bacon","year":"2005","unstructured":"Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's interagency HIV study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12(9):1013\u20139.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"1011_CR35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ije\/dyy021","volume":"47","author":"AA Adimora","year":"2018","unstructured":"Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, et al. Cohort Profile: The Women's Interagency HIV Study (WIHS). Int J Epidemiol. 2018;47(2):393\u20134i.","journal-title":"Int J Epidemiol"},{"key":"1011_CR36","doi-asserted-by":"crossref","unstructured":"Byrd KK, Hou JG, Hazen R, Kirkham H, Suzuki S, Clay PG, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019.","DOI":"10.1097\/QAI.0000000000002142"},{"issue":"4","key":"1011_CR37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","volume":"19","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan S, Detels R, Mehta SH, Macatangay BJ, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601\u201311.","journal-title":"AIDS Behav"},{"issue":"4","key":"1011_CR38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAI.0000000000000643","volume":"69","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan S, Justice AC, Alexander GC, Brown TT, Gandhi NR, McNicholl IR, et al. Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;69(4):493\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1011_CR39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"L Radloff","year":"1977","unstructured":"Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385\u2013401.","journal-title":"Appl Psychol Meas"},{"issue":"1","key":"1011_CR40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121\u201330.","journal-title":"Biometrics."},{"key":"1011_CR41","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: John Wiley & Sons, Inc.; 1987."},{"issue":"22","key":"1011_CR42","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"WM El-Sadr","year":"2006","unstructured":"El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283\u201396.","journal-title":"N Engl J Med"},{"issue":"13","key":"1011_CR43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/QAD.0000000000000316","volume":"28","author":"SH Kim","year":"2014","unstructured":"Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. Aids. 2014;28(13):1945\u201356.","journal-title":"Aids."},{"issue":"1","key":"1011_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10461-012-0159-4","volume":"17","author":"SY Kahana","year":"2013","unstructured":"Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults. AIDS Behav. 2013;17(1):41\u201360.","journal-title":"AIDS Behav"},{"issue":"1","key":"1011_CR45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12889-018-6314-8","volume":"19","author":"AR Bazzi","year":"2019","unstructured":"Bazzi AR, Drainoni ML, Biancarelli DL, Hartman JJ, Mimiaga MJ, Mayer KH, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019;19(1):31.","journal-title":"BMC Public Health"},{"issue":"1","key":"1011_CR46","doi-asserted-by":"crossref","first-page":"21437","DOI":"10.7448\/IAS.20.1.21437","volume":"20","author":"MH Kim","year":"2017","unstructured":"Kim MH, Mazenga AC, Yu X, Ahmed S, Paul ME, Kazembe PN, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors. J Int AIDS Soc. 2017;20(1):21437.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"1011_CR47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/09540120600652303","volume":"19","author":"D Rao","year":"2007","unstructured":"Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28\u201333.","journal-title":"AIDS Care"},{"issue":"1","key":"1011_CR48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/09540120020018161","volume":"13","author":"DA Murphy","year":"2001","unstructured":"Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27\u201340.","journal-title":"AIDS Care"},{"issue":"3","key":"1011_CR49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpedi.157.3.249","volume":"157","author":"DA Murphy","year":"2003","unstructured":"Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249\u201355.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"8","key":"1011_CR50","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/1049732317697674","volume":"27","author":"EL Fields","year":"2017","unstructured":"Fields EL, Bogart LM, Thurston IB, Hu CH, Skeer MR, Safren SA, et al. Qualitative comparison of barriers to antiretroviral medication adherence among perinatally and behaviorally HIV-infected youth. Qual Health Res. 2017;27(8):1177\u201389.","journal-title":"Qual Health Res"},{"key":"1011_CR51","doi-asserted-by":"crossref","unstructured":"Closson K, Palmer A, Salters K, Puskas C, Parashar S, Tiamiyu L, et al. Lower optimal treatment adherence among youth living with HIV in a universal health care setting where ART is available at no cost. J Adolesc Health. 2018.","DOI":"10.1016\/j.jadohealth.2018.10.001"},{"issue":"7","key":"1011_CR52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/09540121.2015.1011073","volume":"27","author":"C Hudelson","year":"2015","unstructured":"Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV\/AIDS in low- and middle-income countries: a systematic review. AIDS Care. 2015;27(7):805\u201316.","journal-title":"AIDS Care"},{"key":"1011_CR53","volume-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain","year":"2016","unstructured":"Kerrigan D, Mantsios A, Margolis D, Murray M, editors. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain. Durban: 21st international AIDS conference; 2016."},{"issue":"1","key":"1011_CR54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018;13(1):e0190487.","journal-title":"PLoS One"},{"issue":"11","key":"1011_CR55","doi-asserted-by":"crossref","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183.","journal-title":"PLoS Med"},{"issue":"11","key":"1011_CR56","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/09540121.2011.565025","volume":"23","author":"A Nel","year":"2011","unstructured":"Nel A, Kagee A. Common mental health problems and antiretroviral therapy adherence. AIDS Care. 2011;23(11):1360\u20135.","journal-title":"AIDS Care"},{"issue":"3","key":"1011_CR57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00126334-200107010-00006","volume":"27","author":"GM Lucas","year":"2001","unstructured":"Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1011_CR58","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00126334-200304150-00009","volume":"32","author":"A Palepu","year":"2003","unstructured":"Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr. 2003;32(5):522\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"1011_CR59","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1360-0443.2008.02269.x","volume":"103","author":"M Malta","year":"2008","unstructured":"Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus\/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242\u201357.","journal-title":"Addiction."},{"issue":"11","key":"1011_CR60","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1086\/503905","volume":"42","author":"GM Lucas","year":"2006","unstructured":"Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42(11):1628\u201335.","journal-title":"Clin Infect Dis"},{"key":"1011_CR61","doi-asserted-by":"crossref","unstructured":"Pokhrel KN, Pokhrel KG, Sharma VD, Poudel KC, Neupane SR, Mlunde LB, et al. Mental health disorders and substance use among people living with HIV in Nepal: their influence on non-adherence to anti-retroviral therapy. AIDS Care. 2019:1\u20139.","DOI":"10.1080\/09540121.2019.1587365"},{"issue":"2","key":"1011_CR62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0B013E31822D490A","volume":"58","author":"JS Gonzalez","year":"2011","unstructured":"Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV\/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1011_CR63","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1007\/s10461-017-2017-x","volume":"22","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable Cabotegravir as PrEP in the context of a phase II trial in the United States. AIDS Behav. 2018;22(11):3540\u20139.","journal-title":"AIDS Behav"},{"issue":"16","key":"1011_CR64","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/01.aids.0000189866.67182.f7","volume":"19","author":"M Gandhi","year":"2005","unstructured":"Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. Aids. 2005;19(16):1885\u201396.","journal-title":"Aids."}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01011-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-020-01011-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-020-01011-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T23:10:18Z","timestamp":1627168218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-020-01011-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1186\/s12905-020-01011-8","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was considered to be exempt by the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health as it was secondary analysis using previously collected, anonymized data. The study team was granted permission from the WIHS Executive Team to access deidentified data and to conduct the current analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"One of the paper co-authors, MM, was formerly at ViiV Healthcare and helped with the conceptualization of the study and the writing of the manuscript. MM is no longer with ViiV Healthcare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}